• Amylyx will present two posters at the Endocrine Society’s ENDO 2026 meeting in Chicago, June 13-16, 2026.
• Data on the U.S. burden of post-bariatric hypoglycemia is scheduled for June 14, 2026.
• Trial-design work for the Phase 3 LUCIDITY study of avexitide in post-bariatric hypoglycemia is slated for June 15, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amylyx Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606080900BIZWIRE_USPR_____20260608_BW097177) on June 08, 2026, and is solely responsible for the information contained therein.